Phaseline

Targets › PPP1CB

PPP1CB (Serine/threonine-protein phosphatase PP1-beta catalytic subunit): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2030.

Protein phosphatase that associates with over 200 regulatory proteins to form highly specific holoenzymes which dephosphorylate hundreds of biological targets. Protein phosphatase (PP1) is essential for cell division, it participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis. (UniProt, P62140)

Open in Phaseline: the race on PPP1CB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AskBioAB-1002
Protein phosphatase 1 catalytic subunit beta (PP1β) inhibitor delivered via intracoronary
PPP1CBPhase 2Congestive Heart FailureDec 2030

Conditions

Congestive Heart Failure (1)

Modalities

other (1)

Companies

AskBio (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.